Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) had its price objective upped by research analysts at Guggenheim from $20.00 to $22.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price objective points to a potential upside of 183.72% from the stock's current price.
Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Thursday. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Finally, Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zevra Therapeutics has a consensus rating of "Buy" and a consensus target price of $21.86.
View Our Latest Stock Report on Zevra Therapeutics
Zevra Therapeutics Trading Down 2.1 %
Shares of ZVRA stock traded down $0.17 on Thursday, reaching $7.75. The company had a trading volume of 257,733 shares, compared to its average volume of 410,567. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market cap of $413.88 million, a PE ratio of -3.93 and a beta of 1.98. The company has a 50-day moving average of $7.95 and a 200-day moving average of $8.14.
Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. On average, equities analysts forecast that Zevra Therapeutics will post -1.95 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares of the company's stock, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by insiders.
Institutional Trading of Zevra Therapeutics
Several institutional investors have recently added to or reduced their stakes in ZVRA. BNP Paribas Financial Markets purchased a new stake in shares of Zevra Therapeutics during the fourth quarter worth about $53,000. XTX Topco Ltd purchased a new stake in Zevra Therapeutics in the third quarter worth about $94,000. China Universal Asset Management Co. Ltd. purchased a new position in Zevra Therapeutics during the fourth quarter valued at $94,000. Intech Investment Management LLC bought a new stake in Zevra Therapeutics during the 3rd quarter valued at about $95,000. Finally, Virtu Financial LLC purchased a new position in Zevra Therapeutics in the 3rd quarter worth approximately $127,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.
About Zevra Therapeutics
(
Get Free Report)
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zevra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.
While Zevra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
